Tazarotene topical Alternatives Compared
| Tazarotene topical | Stelara | Skyrizi |
|
|---|
| Tazarotene topical | Stelara (ustekinumab) | Skyrizi (risankizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Tazarotene topical is a retinoid preparation that may be used to treat psoriasis, acne, or photoaging. It is available as a cream, gel, foam, or lotion, and itching, burning, redness, stinging... View more |
Prescription only
Stelara is an immunosuppressant medication that works by binding to two inflammatory cytokines, IL-12 and IL-23, which have been identified as important contributors to chronic inflammation. Stelara... View more |
Prescription only
Skyrizi is an interleukin inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis (UC). The usual dosage is 150mg every 12 weeks... View more |
Related suggestions |
|||||||||||||||||||||||
| More about Tazarotene topical | More about Stelara (ustekinumab) | More about Skyrizi (risankizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Tazarotene topical has an average rating of 7.3 out of 10 from a total of 74 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 25% reported a negative effect. |
Stelara has an average rating of 7.6 out of 10 from a total of 244 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 15% reported a negative effect. |
Skyrizi has an average rating of 8.0 out of 10 from a total of 47 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 16% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: tazarotene topical side effects in more detail. |
See also: Stelara side effects in more detail. |
See also: Skyrizi side effects in more detail. |
||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all tazarotene topical prices |
View all Stelara prices |
View all Skyrizi prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Arazlo, Avage, Fabior, Tazorac | Other ustekinumab brands include: Pyzchiva, Selarsdi, Wezlana |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
18 hours |
1291.2 hours |
672 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 12 drugs are known to interact with tazarotene topical:
|
A total of 453 drugs are known to interact with Stelara:
|
A total of 163 drugs are known to interact with Skyrizi:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
June 13, 1997 |
September 25, 2009 |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.